The Effect of Taurine on the Clinical Course and Mid-Term Prognosis of Chronic Heart Failure in Patients with Ischemic Heart Disease

Abstract

In this work, we studied the effect of taurine on the clinical manifestations of heart failure in patients with ischemic heart disease, the functional state of the cardiovascular system, the level of biomarkers and the prognosis of the disease.  The effectiveness of the additional use of taurine for the treatment of chronic heart failure (CHF) is beyond doubt, which is due to the ability of the drug to reduce tissue ischemia and hypoxia. At the background of 12-month therapy with taurine at a dose of 750 mg per day, 56% of patients with chronic heart failure II and III functional class (FC) (according to New York Heart Association (NYHA), due to ischemic heart disease, there is a significant decrease in the functional class of CHF (p <0.01).